Fagron NV logo

Fagron NV (4A5)

Market Closed
12 Dec, 20:00
XFRA XFRA
20. 55
+0.15
+0.74%
- Market Cap
18.45 P/E Ratio
1.08% Div Yield
1,675 Volume
0.99 Eps
20.4
Previous Close
Day Range
20.55 20.55
Year Range
16.3 22.7
Want to track 4A5 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 60 days

Summary

4A5 closed yesterday higher at €20.55, an increase of 0.74% from Thursday's close, completing a monthly decrease of -2.61% or €0.55. Over the past 12 months, 4A5 stock gained 23.35%.
4A5 is not paying dividends to its shareholders.
The last earnings report, released on Jul 31, 2025, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports. The next scheduled earnings report is due on Feb 12, 2026.
The stock of the company had never split.
The company's stock is traded on 7 different exchanges and in various currencies, with the primary listing on XBRU (EUR).

4A5 Chart

Fagron NV (4A5) FAQ

What is the stock price today?

The current price is €20.55.

On which exchange is it traded?

Fagron NV is listed on XBRU.

What is its stock symbol?

The ticker symbol is 4A5.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 1.08%.

What is its market cap?

As of today, no market cap data is available.

When is the next earnings date?

The next earnings report will release on Feb 12, 2026.

Has Fagron NV ever had a stock split?

No, there has never been a stock split.

Fagron NV Profile

Specialty Retail Industry
Consumer Discretionary Sector
Mr. Rafael Padilla CEO
XFRA Exchange
BE0003874915 ISIN
BE Country
3,828 Employees
19 May 2025 Last Dividend
- Last Split
- IPO Date

Overview

Fagron NV is a globally operating pharmaceutical compounding company, dedicated to offering personalized pharmaceutical care to a broad range of healthcare facilities and patients. The company categorizes its operations into three main segments: Essentials, Brands, and Compounding Services. It is actively engaged in the innovation of concepts, vehicles, and formulations to advance pharmaceutical compounding. Founded in 1990 and originally known as Arseus NV, the company underwent a name change to Fagron NV in January 2015 and has since established its base in Nazareth, Belgium. Fagron's mission is to bridge the gap between the unique needs of patients and the capabilities of the pharmaceutical industry by providing custom solutions. To support this mission, it also runs the Fagron Academy, which offers education and training to pharmacists and prescribers.

Products and Services

  • DiluCap: These are a range of excipients designed to assist in the compounding of capsule formulations, catering to a variety of pharmaceutical needs.
  • Imuno TF Complex: This product aids in the regulation of immune responses, offering support in immune system regulation.
  • Pigmerise: Targeted at those suffering from hypopigmentation disorders, Pigmerise utilizes a natural phytocomplex to address these conditions.
  • Pentravan: A cream base designed to enhance the delivery of medications by avoiding first-pass metabolism and preventing gastrointestinal erosion, thus ensuring effective therapy.
  • Nourisil MD: Recommended as a first line therapy, this product aids in the prevention and treatment of scars and keloids, offering both curative and preventive benefits for skin health.
  • Neogen: This line of hair care products addresses various needs and conditions, including hair loss, with a focus on promoting hair health and growth.
  • TrichoConcept: Specifically formulated for the treatment of alopecia, this range offers targeted solutions for those experiencing hair loss.
  • Fagron Advanced Derma: Focused on skincare, this portfolio covers basic skin care needs, compound pharmaceutical treatment options, and personalized dermatological care, catering to individual requirements.
  • SyrSpend SF: This range ensures pharmaceutical stability, consistency in dosage, and patient comfort, improving the overall medication administration experience.

Contact Information

Address: Venecoweg 20A
Phone: 32 8 001 28 80